SEARCH

Entries in Actos (3)

Wednesday
Mar232011

Actos May Prevent Type II Diabetes

Jeffrey Hamilton/Thinkstock(AUSTIN, Texas) -- Much attention has come to the use of glitazones, a class of drugs for the treatment of diabetes, especially in light of the Avandia (rosiglitazone) black box warnings.  Avandia is associated with an increased risk of heart attacks and has been taken off the market in Europe. However, Actos (piolitazone), has fewer side effects and is still used as a therapy for type 2 diabetes. 

In this study, conducted by University of Texas Health Science Center and published in the New England Journal of Medicine, over 600 participants who have elevated blood sugar, a risk factor for developing type 2 diabetes, were given either Actos or a placebo and then followed for 2.4 years.  Results of the study show participants in the Actos group were 72 percent less likely to develop diabetes than those taking placebo. 

This is a modest improvement over lifestyle change alone, which can lead to a 58-percent decrease in progression to diabetes.  Patients in the Actos group also had slightly lower blood pressure, less plaque buildup in arteries, and an improvement in cholesterol.  However, patients taking Actos had more weight gain and leg swelling than those on placebo. 

It is not clear weather this medication will benefit patients in the long term or actually decrease complications from diabetes down the line. ´╗┐

Copyright 2011 ABC News Radio

Thursday
Mar172011

New Analysis Reinforces Links Between Avandia and Heart Problems

Medioimages/Photodisc/Thinkstock(NORWICH, England) -- In 2010, the FDA announced that it would significantly restrict the use of Rosiglitazone, popularly known as Avandia, a drug used to treat type 2 diabetes after the drug was associated with a higher risk of heart attacks.

Now, a new review study from the University of East Anglia in Norwich, England adds more weight to the mounting evidence of the drug being associated with heart problems.

Researchers from the U.S. and UK analyzed the results of 16 studies that directly compare the risk of heart problems for two drugs popularly known as Actos and Avandia. Both the drugs are used to treat type 2 diabetes.

The team found that, compared with Actos, Avandia was associated with a slightly increased risk of heart problems.  However, the researchers noted that both drugs belong to the same class and are known to be associated with heart problems.

While the drug remains on the market in the United States, the use of Avandia has been suspended in Europe since September 2010.

Copyright 2011 ABC News Radio´╗┐

Friday
Sep242010

FDA Looks Into Diabetes Drug 'Actos' For Risk Of Cancer

Photo Courtesy -- ABC News(NEW YORK) -- According to reports by WebMD, The FDA has launched a safety review of the diabetes drug Actos in light of new data suggesting that the drug may increase risk of bladder cancer.  While not considered a serious enough risk to prevent FDA approval, earlier animal and human studies linked Actos to bladder cancer.  As a condition of approval, the FDA insisted that Actos maker Takeda Pharmaceuticals look for bladder cancer in patients taking the drug.  Now five years in to Takeda's 10-year study, the overall data is reassuring.  WebMD urges patients taking Actos that they do not have an increased risk of bladder cancer.  However, when researchers looked only at patients who had taken Actos the longest, and who had accumulated the highest lifetime dose of the drug, they found risk emerged in patients who had taken Actos for at least 24 months.  The FDA stresses that the finding is not proof that Actos causes bladder cancer. WebMD warned that Patients who are taking Actos are advised not to stop taking their medication unless advised to do so by their health care provider.  Concerned patients should discuss the new information with their doctors.  Actos is widely considered to be safer than Avandia, the only other approved diabetes drug in its class. The FDA is currently considering whether Avandia should remain on the market. An FDA expert advisory panel recently split over the issue.

Copyright 2010 ABC News Radio

 







ABC News Radio